CTLs can reduce the intra-tumoral GSH content by up-regulating γ-glutamyltransferase and promoting IFN-γ secretion from T cells via JAK/STAT1 activation, which sensitizes tumor cells to cisplatin-induced apoptosis [113]. The gene discussed is IFNG; the disease is neoplasm.